Audrey Lee-Gosselin

Audrey Lee-Gosselin

Auto-generated profile, based on publicly available information

Audrey Lee-Gosselin

Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in NeuroImage
Verified
Journal Article
Open access
DMDavid Maresca
David Maresca
TPThomas Payen
Thomas Payen
ALAudrey Lee-Gosselin
Audrey Lee-Gosselin
BLBill Ling
Bill Ling
DMDina Malounda
Dina Malounda
MSMikhail G. Shapiro
Mikhail G. Shapiro
Hemodynamic functional ultrasound imaging (fUS) of neural activity provides a unique combination of spatial coverage, spatiotemporal resolution and compatibility with freely moving animals. However, deep and transcranial monitoring of brain activity and the imaging of dynamics in slow-flowing blood vessels remains challenging. To enhance fUS capabilities, we introduce biomolecular hemodynamic enhancers based on gas vesicles (GVs), genetically encodable ultrasound contrast agents derived from buoyant photosynthetic microorganisms. We show that intravenously infused GVs enhance ultrafast Doppler ultrasound contrast and visually-evoked hemodynamic contrast in transcranial fUS of the mouse brain. This hemodynamic contrast enhancement is smoother than that provided by conventional microbubbles, allowing GVs to more reliably amplify neuroimaging signals.

14 April 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
AKAditi Khatpe
Aditi Khatpe
RDRebecca Dirks
Rebecca Dirks
PBPoornima Bhat-Nakshatri
Poornima Bhat-Nakshatri
HMHenry Mang
Henry Mang
KBKatie Batic
Katie Batic
HNHarikrishna Nakshatri
Harikrishna Nakshatri
Study of genomic aberrations leading to immortalization of epithelial cells has been technically challenging due to the lack of isogenic models. To address this, we used healthy primary breast luminal epithelial cells of different genetic ancestry and their hTERT-immortalized counterparts to identify transcriptomic changes associated with immortalization. Elevated expression of TONSL (Tonsoku-like, DNA repair protein) was identified as one of the earliest events during immortalization. TONSL, which is located on chromosome 8q24.3, was found to be amplified in approximately 20% of breast cancers. TONSL alone immortalized primary breast epithelial cells and increased telomerase activity, but overexpression was insufficient for neoplastic transformation. However, TONSL-immortalized primary cells overexpressing defined oncogenes generated estrogen receptor–positive adenocarcinomas in mice. Analysis of a breast tumor microarray with approximately 600 tumors revealed poor overall and progression-free survival of patients with TONSL-overexpressing tumors. TONSL increased chromatin accessibility to pro-oncogenic transcription factors, including NF-κB and limited access to the tumor-suppressor p53. TONSL overexpression resulted in significant changes in the expression of genes associated with DNA repair hubs, including upregulation of several genes in the homologous recombination (HR) and Fanconi anemia pathways. Consistent with these results, TONSL-overexpressing primary cells exhibited upregulated DNA repair via HR. Moreover, TONSL was essential for growth of TONSL-amplified breast cancer cell lines in vivo, and these cells were sensitive to TONSL–FACT complex inhibitor CBL0137. Together, these findings identify TONSL as a regulator of epithelial cell immortalization to facilitate cancer initiation and as a target for breast cancer therapy. Significance: The chr.8q24.3 amplicon-resident gene TONSL is upregulated during the initial steps of tumorigenesis to support neoplastic transformation by increasing DNA repair and represents a potential therapeutic target for treating breast cancer.

10 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
ALAudrey Lee-Gosselin
Audrey Lee-Gosselin
NJNur Jury-Garfe
Nur Jury-Garfe
YYYanwen You
Yanwen You
LDLuke Child Dabin
Luke Child Dabin
DSDisha Soni
Disha Soni
CLCristian Lasagna-Reeves
Cristian Lasagna-Reeves
The role of TREM2 in Alzheimer’s disease (AD) is not fully understood. Previous studies investigating the effect of TREM2 deletion on tauopathy mouse models without the contribution of b-amyloid have focused only on tau overexpression models. Herein, we investigated the effects of TREM2 deficiency on tau spreading using a mouse model in which endogenous tau is seeded to produce AD-like tau features. We found that Trem2−/− mice exhibit attenuated tau pathology in multiple brain regions concomitant with a decreased microglial density. The neuroinflammatory profile in TREM2-deficient mice did not induce an activated inflammatory response to tau pathology. These findings suggest that reduced TREM2 signaling may alter the response of microglia to pathological tau aggregates, impairing their activation and decreasing their capacity to contribute to tau spreading. However, caution should be exercised when targeting TREM2 as a therapeutic entry point for AD until its involvement in tau aggregation and propagation is better understood.

29 April 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAvinoam Bar-Zion
Avinoam Bar-Zion
ANAtousa Nourmahnad
Atousa Nourmahnad
DMDavid R. Mittelstein
David R. Mittelstein
SYSangjin Yoo
Sangjin Yoo
DMDina Malounda
Dina Malounda
MSMikhail G. Shapiro
Mikhail G. Shapiro
Recent advances in molecular engineering and synthetic biology have made it possible for biomolecular and cell-based therapies to provide highly specific disease treatment. However, both the ability to spatially target the action of such therapies, and their range of effects on the target tissue remain limited. Here we show that biomolecules and cells can be engineered to deliver potent mechanical effects at specific locations inside the body under the direction of focused ultrasound. This capability is based on gas vesicles, a unique class of air-filled protein nanostructures derived from buoyant photosynthetic microbes. We show that low-frequency ultrasound can convert these nanoscale biomolecules into micron-scale cavitating bubbles, as demonstrated with acoustic measurements and ultrafast optical microscopy. This allows gas vesicles targeted to cell-surface receptors to serve as remotely detonated cell-killing agents. In addition, it allows cells genetically engineered to express gas vesicles to be triggered with ultrasound to lyse and release therapeutic payloads. We demonstrate these capabilities in vitro , in cellulo , and in vivo . This technology equips biomolecular and cellular therapeutics with unique capabilities for spatiotemporal control and mechanical action.

25 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MAMohamad H. Abedi
Mohamad H. Abedi
MYMichael S. Yao
Michael S. Yao
DMDavid R. Mittelstein
David R. Mittelstein
ABAvinoam Bar-Zion
Avinoam Bar-Zion
MSMargaret Swift
Margaret Swift
MSMikhail G. Shapiro
Mikhail G. Shapiro
Rapid advances in synthetic biology are driving the development of genetically engineered microbes as therapeutic agents for a multitude of human diseases, including cancer. In particular, the immunosuppressive microenvironment of solid tumors creates a favorable niche for systemically administered bacteria to engraft in the tumor and release therapeutic payloads. However, such payloads can be harmful if released in healthy tissues where the bacteria also engraft in smaller numbers. To address this limitation, we engineer therapeutic bacteria to be controlled by focused ultrasound, a form of energy that can be applied noninvasively to specific anatomical sites such as solid tumors. This control is provided by a temperature-actuated genetic state switch that produces lasting therapeutic output in response to briefly applied focused ultrasound hyperthermia. Using a combination of rational design and high-throughput screening we optimized the switching circuits of engineered cells and connected their activity to the release of immune checkpoint inhibitors. In a clinically relevant cancer model, ultrasound-activated therapeutic microbes successfully turned on in situ and induced a marked suppression of tumor growth. This technology provides a critical tool for the spatiotemporal targeting of potent bacterial therapeutics in a variety of biological and clinical scenarios.

24 November 2025
Verified
Other
Open access
AKAditi Khatpe
Aditi Khatpe
RDRebecca Dirks
Rebecca Dirks
PBPoornima Bhat-Nakshatri
Poornima Bhat-Nakshatri
HMHenry Mang
Henry Mang
KBKatie Batic
Katie Batic
HNHarikrishna Nakshatri
Harikrishna Nakshatri
Contains additional materials and methods and supplementary figures